BEAT: heart attack detection progress and lower cash burn in the third quarter
According to TradingView, BEAT reported regulatory and clinical progress in heart attack detection and a smaller quarterly cash burn.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
BEAT said that in the third quarter it reached important regulatory and clinical milestones in heart attack detection. Cost cuts reduced its quarterly cash outflow and losses. Guidance for operating cash outflow in fiscal 2026 is between $12 million and $12.5 million. A pivotal U.S. study is targeted to begin by the first quarter of 2027. The information comes from TradingView, which notes that its text is an AI-generated summary and may contain inaccuracies.
why it matters
For investors in small medtech companies, the timing of the study and the pace of cash burn remain the key points, since they determine how much funding the company will need.
tags
instruments
on polymarket
sources
- BEAT: Clinical and FDA progress advanced heart attack detection as cash burn declined — TradingView, 12 November 2026 at 23:37 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗